Jumbo and Hanshow announce a new partnership to digitize over 700 stores
23.11.2022 10:00:00 EET | Business Wire | Press release
Jumbo, the second largest supermarket chain in the Netherlands which also has stores in Belgium, has announced an exclusive partnership with global retail solutions provider Hanshow to digitally transform its network of stores.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221117005660/en/
Hanshow's electronic shelf labels (ESLs) installed at Jumbo (Photo: Business Wire)
Jumbo was founded in 1921 and currently owns more than 700 stores in the Netherlands and Belgium. It is locally renowned for its wide range of selections and personalized attention to both customers and employees.
With the digital transformation of its business model, Jumbo is becoming one of the leading retailers in Europe. This is driven in part by the Jumbo Tech Campus which facilitates the innovation of Jumbo’s digital solutions and channels to connect its online and offline retail business while strengthening relationships with customers.
The collaboration with Hanshow is a crucial move in Jumbo's digitization strategy. To date, Hanshow’s solutions have been rolled out in over 250 stores. Soon Jumbo will have upgraded all 700 of its stores, with over 11 million Hanshow electronic price tags installed.
“The unique Jumbo formula revolves around a large assortment with the best service at low prices. Correct prices on the shelf and the ability to react quickly and efficiently to market developments are essential for this. The technology of Hanshow contributes to this.” Jumbo said.
At the heart of this digital transformation with Hanshow, the adoption of over 11 million electronic shelf labels (ESLs) will save time and energy across all Jumbo stores. Hundreds of thousands of paper price tags can be saved by this partnership each year, which is also in line with Jumbo’s abiding goal of sustainability. ESLs dramatically increase efficiency for retail operations such as inventory management and faster order picking with LED flashing functions. Additionally, ESLs improve the customer shopping experience with centralized price updates, error-free labeling, and enhanced store appearance.
Powering the systems management of this massive amount of ESL is made possible by adopting the Hanshow SaaS solution via Microsoft Azure. Benefits for Jumbo include reducing costs spent on infrastructure and servers, and if needed the Hanshow technical support team is capable of helping resolve technical issues much faster. Hanshow’s PriSmart ESL and IoT device management system also allows Jumbo to get the systems up and running sooner and the ability to manage and update its pricing network in a faster, more secure, and more accessible way.
“Hanshow solutions can drive sustainability, improve efficiency, eliminate waste, and create new opportunities for Jumbo stores,” notes Sally Liang, General Manager of Europe, Hanshow. “This is an exciting era for retail, and we’re proud to be partnering with a company like Jumbo that is committed to improving its customer experience and operational efficiency through digital retail transformation.”
The cooperation with Jumbo is a significant achievement for Hanshow’s international development. In the future, Hanshow looks forward to cooperating with global customers to further explore the paths of digital transformation, to further optimize digital store solutions, and to provide more comprehensive, intelligent, and efficient digital service upgrades.
About Hanshow
Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions, offering global customers a series of world-class customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow’s solutions are used by over 30,000 stores in more than 50 countries, helping retailers streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005660/en/
Contact information
Joy Wang
tianjiao.wang@hanshow.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom